Trophic effect of β-amyloid precursor protein on cerebral cortical neurons in culture

doi:10.1016/S0006-291X(05)81412-3

Biochemical and Biophysical Research Communications

Volume 181, Issue 1, 27 November 1991, Pages 265-271

https://doi.org/10.1016/S0006-291X(05)81412-3 Get rights and content

Summary

We investigated the effect of human β-amyloid precursor protein (APP) on rat primary cerebral cortical neurons cultured in a serum-free medium. Two secretory APP species (APP667 and APP592) with and without the protease inhibitor domain were produced by COS-1 cells transfected with APP cDNAs, which encode the N-terminal portions of APP770 and APP695. Both highly purified APP species, when added to the medium, enhanced neuronal survival and neurite extension in a dose-dependent manner with a maximum effect at approximately 100 nM. These results suggest that secreted forms of APP have trophic activity for cerebral cortical neurons.

References (26)

GlennerG.G. et al.
Biochem. Biophys. Res. Comm.
(1984)
NeveR.L. et al.
Neuron
(1988)
TanakaS. et al.
Biochem. Biophys. Res. Comm.
(1989)
WeidemannA. et al.
Cell
(1989)
SaitohT. et al.
Cell
(1989)
SchubertD. et al.
Neuron
(1989)
ChenM. et al.
Neurosci. Lett.
(1991)
RoherA.E. et al.
Biochem. Biophys. Res. Comm.
(1991)
KitaguchiN. et al.
Biochem. Biophys. Res. Comm.
(1990)
KitaguchiN. et al.
Biochim. Biophys. Acta
(1990)

SelkoeD.J.

Neuron

(1991)

MastersC.L. et al.

KangJ. et al.

Nature

(1987)

Cited by (200)

Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease
2021, Brain Research
Alzheimer’s disease (AD) is the leading form of dementia but lacks curative treatments. Current understanding of AD aetiology attributes the development of the disease to the misfolding of two proteins; amyloid-β (Aβ) and hyperphosphorylated tau, with their pathological accumulation leading to concomitant oxidative stress, neuroinflammation, and neuronal death. These processes are regulated at multiple levels to maintain homeostasis and avert disease. However, many of the relevant regulatory proteins appear to be downregulated in the AD-afflicted brain. Enhancement/restoration of these ‘protective’ proteins, therefore, represents an attractive therapeutic avenue. Gene therapy is a desirable means of achieving this because it is not associated with the side-effects linked to systemic protein administration, and sustained protein expression virtually eliminates compliance issues. The current article represents a focused and succinct review of the better established ‘protective’ protein targets for gene therapy enhancement/restoration rather than being designed as an exhaustive review incorporating less validated protein subjects. In addition, we will discuss how the risks associated with uncontrolled or irreversible gene expression might be mitigated through combining neuronal-specific promoters, inducible expression systems and localised injections. Whilst many of the gene therapy targets reviewed herein are yet to enter clinical trials, preclinical testing has thus far demonstrated encouraging potential for the gene therapy-based treatment of AD.
Secreted amyloid precursor protein alpha activates neuronal insulin receptors and prevents diabetes-induced encephalopathy
2018, Experimental Neurology
Secreted amyloid precursor protein alpha (sAPPα) is a potent neurotrophin in the CNS but a dedicated receptor has not been found. However, protein interactions involving amyloid beta (Aβ), a peptide cleaved from the same parent peptide as sAPPα, indicate that insulin receptors (IRs) could be a target of amyloid peptides. In this study, in vitro analysis of cortical neuronal cultures revealed that exogenous sAPPα increased IR phosphorylation in the absence of insulin. Furthermore, in an APP overexpressing mouse model, sAPPα bound IRs in the cortex with significantly greater binding in hypoinsulinemic animals. To further examine the effects of sAPPα on the diabetic brain, we next rendered sAPPα overexpressing mice insulin depleted and found that sAPPα blocked aberrant tau phosphorylation (T231) in cortical tissue after 16 weeks diabetes. sAPPα overexpression also prevented hyperphosphorylation of AKT/GSK3 and activation of the unfolded protein response (UPR). In total, these data show sAPPα binds and activates neuronal IRs and that sAPPα has a protective effect on diabetic brain tissue.
The amyloid precursor protein represses expression of acetylcholinesterase in neuronal cell lines
2013, Journal of Biological Chemistry
The toxic role of amyloid β peptides in Alzheimer's disease is well documented. Their generation is via sequential β- and γ-secretase cleavage of the membrane-bound amyloid precursor protein (APP). Other APP metabolites include the soluble ectodomains sAPPα and sAPPβ and also the amyloid precursor protein intracellular domain (AICD). In this study, we examined whether APP is involved in the regulation of acetylcholinesterase (AChE), which is a key protein of the cholinergic system and has been shown to accelerate amyloid fibril formation and increase their toxicity. Overexpression of the neuronal specific isoform, APP₆₉₅, in the neuronal cell lines SN56 and SH-SY5Y substantially decreased levels of AChE mRNA, protein, and catalytic activity. Although similar decreases in mRNA levels were observed of the proline-rich anchor of AChE, PRiMA, no changes were seen in mRNA levels of the related enzyme, butyryl-cholinesterase, nor of the high-affinity choline transporter. A γ-secretase inhibitor did not affect AChE transcript levels or enzyme activity in SN56 (APP₆₉₅) or SH-SY5Y (APP₆₉₅) cells, showing that regulation of AChE by APP does not require the generation of AICD or amyloid β peptide. Treatment of wild-type SN56 cells with siRNA targeting APP resulted in a significant up-regulation in AChE mRNA levels. Mutagenesis studies suggest that the observed transcriptional repression of AChE is mediated by the E1 region of APP, specifically its copper-binding domain, but not the C-terminal YENTPY motif. In conclusion, AChE is regulated in two neuronal cell lines by APP in a manner independent of the generation of sAPPα, sAPPβ, and AICD.
Background: Acetylcholinesterase (AChE) and amyloid precursor protein (APP) are implicated in Alzheimer's disease, but their specific biological roles remain unclear.
Results: Overexpression or knockdown of neuronal APP modulates AChE mRNA, protein levels, and enzyme activity.
Conclusion: APP can act as a transcriptional regulator through a novel mechanism independently of γ-secretase.
Significance: Understanding the physiological functions of APP will lead to a greater understanding of Alzheimer's disease etiology.
ARNO is recruited by the neuronal adaptor FE65 to potentiate ARF6-mediated neurite outgrowth
2022, Open Biology
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients
2022, Nature Aging
The Amyloid Precursor Protein Plays Differential Roles in the UVA Resistance and Proliferation of Human Retinal Pigment Epithelial Cells
2022, Protein and Peptide Letters

View all citing articles on Scopus

View full text

Trophic effect of β-amyloid precursor protein on cerebral cortical neurons in culture

Summary

Biochem. Biophys. Res. Comm.

Neuron

Biochem. Biophys. Res. Comm.

Cell

Cell

Neuron

Neurosci. Lett.

Biochem. Biophys. Res. Comm.

Biochem. Biophys. Res. Comm.

Biochim. Biophys. Acta

Neuron

Nature